# Advanced Glycation Endproducts and Cardio-Renal Disease

> **NIH NIH K24** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2020 · $121,219

## Abstract

PROJECT SUMMARY/ABSTRACT
 The current application proposes to advance the candidate's program in patient-oriented
research through formal training in omics science and mentorship, through an increased level of
mentoring of young investigators, and through a research project that will build on the
candidate's previous work and afford opportunities to develop his omics research portolio. The
research project aims to close knowledge gaps regarding the significance of key advanced
glycation endproducts (AGEs) to cardiovascular and renal disease in the general population. To
this end, it will undertake gold-standard measurement of a panel comprising the major plasma
AGEs, and particularly the quantitatively and functionally most important adducts, methylglyoxal
hydroimidazolone (MG-H1) and 3-deoxyglucosone-hydroimidazolones (3DG-H), which have
scarcely been evaluated in general clinical or population settings to date. For Aim 1, the project
will leverage an ongoing study applying state-of-the-art echocardiography and magnetic
resonance imaging (MRI) in women with, or at risk for HIV infection, in the Women's
Interagency HIV Study (WIHS) to evaluate the relation of plasma AGEs to abnormal myocardial
mechanics and fibrosis in this high-risk population. For Aims 2 and 3, the project will parlay the
availability of serial measures of glomerular filtration and standardized ascertainment of
cardiovascular events among middle-aged to older adults from the Multi-Ethnic Study of
Atherosclerosis (MESA) to investigate the associations of plasma AGEs with progression of
chronic kidney disease and incident cardiovascular disease. These studies will provide trainees
with a range of exposures to clinical and epidemiologic research to allow their development as
investigators. Further, availability genetic/genomic, epigenomic, transcriptomic and metabolomic
data in MESA will permit exploration of the omic correlates of AGE levels, setting the stage for
larger-scale investigations in the future. Hence, the combination of formal coursework,
increased mentorship, and the leveraging of existing research infrastructure to address research
questions of major clinical importance will provide the candidate with increased capabilities for
POR in precision medicine, and afford opportunities for the growth of his mentees as
researchers in this and other disciplines.

## Key facts

- **NIH application ID:** 10000127
- **Project number:** 5K24HL135413-04
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** JORGE R KIZER
- **Activity code:** K24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $121,219
- **Award type:** 5
- **Project period:** 2017-07-15 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10000127

## Citation

> US National Institutes of Health, RePORTER application 10000127, Advanced Glycation Endproducts and Cardio-Renal Disease (5K24HL135413-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10000127. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*